Desmoid Tumors Market Size is anticipated to increase during the Study Period of 2019-2032

The Desmoid Tumors Market is expected to grow significantly owing to the use of Desmoid Tumors inhibitors in statin-intolerant patients, promising future strategies of Desmoid Tumors, and implications of Desmoid Tumors in broader therapy area.

The Desmoid Tumors market report provides current treatment practices, Desmoid Tumors emerging drugs, Desmoid Tumors market share of the individual therapies, current and forecasted Desmoid Tumors market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Desmoid Tumors treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Desmoid Tumors Market Report

• In 2022, the total treated cases of Desmoid Tumors in the US were ~7,000 which are estimated to increase by 2032. According to the DelveInsight estimates, in 2022, around 3,000 cases progress from first line to second line in the US.

• According to the DelveInsight's analysis, approximately 90% of the prevalent cases are diagnosed in the US, which were found to be around 13,000 cases in 2022.

• The leading Desmoid Tumors Companies includes SpringWorks Therapeutics, Ayala Therapeutics, Iterion Therapeutics, and others.

• Promising Desmoid Tumors pipeline therapies includes Tegavivint, AL102, Nirogacestat, and others.

To discover which therapies are expected to grab the major Desmoid Tumors Market share, click here for Desmoid Tumors Market Research Report @ https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Desmoid Tumors Overview

Desmoid Tumors (DT) are noncancerous growths that develop in connective tissue. They are also called aggressive fibromatosis as they have similarities with a malignant (cancerous) tumor called fibrosarcoma. However, it is considered benign because it does not metastasize (spread) to other parts of the body. The myofibroblast is the cell responsible for the desmoid tumor. A desmoid tumor can invade surrounding

Latest Developmental Activities in the Desmoid Tumors Treatment Landscape

• The FDA granted Orphan Drug Designation for nirogacestat for the treatment of desmoid tumors and Fast Track and Breakthrough Therapy Designations for nirogacestat for the treatment of adult patients with progressive, unresectable, recurrent, or refractory desmoid tumors or deep fibromatosis. The European Commission has also granted Orphan Drug Designation to nirogacestat for the treatment of soft tissue sarcoma. SpringWorks has licensed nirogacestat from Pfizer in August 2017.

• In May 2022, the company announced positive topline results from the DeFi trial. The results suggested that the DeFi trial met its primary endpoint of improving progression-free survival (PFS), demonstrating a statistically significant improvement for nirogacestat over placebo, with a 71% reduction in the risk of disease progression. In addition, the trial met all key secondary endpoints, with nirogacestat demonstrating statistically significant improvements as compared to placebo in ORR and patient-reported outcomes (PROs).

• Ayala Therapeutics, is developing AL102 for the treatment of desmoid tumors. AL102 is currently being studied in Phase II/III pivotal RINGSIDE trial for the treatment of patients with progressing desmoid tumors, which can potentially be used as a registrational study. AL102 is a potent, selective, oral gamma secretase inhibitor.

• In February 2022, the company announced completion of enrollment in Part A of the RINGSIDE trial, with Part B expected to commence immediately thereafter. The company obtained an exclusive, worldwide license to develop and commercialize AL102 from Bristol-Myers Squibb Company, in November 2017.

Desmoid Tumors Epidemiology Segmentation in the 7MM
• Total Desmoid Tumors Prevalent Cases
• Desmoid Tumors Gender-specific Cases
• Total Desmoid Tumors Treated Cases
• Total Desmoid Tumors Diagnosed Cases
• Desmoid Tumors Site-specific Cases

Download the report to understand which factors are driving Desmoid Tumors epidemiology trends, click here for Desmoid Tumors epidemiology segmentation @ https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Desmoid Tumors Treatment Market
The current treatment of desmoid tumor is mainly dominated by the surgery, radiation therapy, systemic therapy and chemotherapy however, under these regimens, many patients suffer a relapse or develop recurrent tumors that are resistant or refractory to further therapy. The inability of current market offerings to alter the natural course of the disease and improve patients' quality of life indicates that there is an unmet need for drugs with better efficacy profiles.

Desmoid Tumors Market Dynamics
The dynamics of the Desmoid Tumors market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as SpringWorks Therapeutics, Ayala Therapeutics, Iterion Therapeutics, and some others are involved in developing drugs for desmoid tumors. The launch of potential emerging therapies such Nirogacestat (SpringWorks Therapeutics), AL102 (Ayala Therapeutics), Tegavivint (Iterion Therapeutics) and others are expected to change the treatment landscape during the forecast period (2022-2032).

To know more about Desmoid Tumors Medications, visit Desmoid Tumors Ongoing Clinical Trials @ https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Desmoid Tumors Market Report

• Coverage- 7MM

• Desmoid Tumors Companies- SpringWorks Therapeutics, Ayala Therapeutics, Iterion Therapeutics, and others.

• Desmoid Tumors Pipeline Therapies- Tegavivint, AL102, Nirogacestat, and others

• Desmoid Tumors Market Dynamics: Desmoid Tumors Market Drivers and Barriers

• Desmoid Tumors Market Access and Reimbursement

To discover more about Desmoid Tumors Market Drugs in development, click here for Desmoid Tumors Market Dynamics and Desmoid Tumors Market Drivers & Barriers @ https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. SWOT Analysis
6. Epidemiology and Market Forecast Methodology
7. Desmoid Tumors: Market Overview (%) at a Glance
8. Disease Background and Overview
9. Epidemiology and Patient Population
10. Country-Specific Patient Population of Desmoid Tumors
11. Current Treatment and Medical Practices
12. Patient Journey
13. Key Endpoint of Clinical Trials
14. Emerging Therapies
15. Desmoid Tumors: Market Size of 7MM
16. Country-Wise Market Analysis (2019-2032)
17. Market Access and Reimbursement
18. Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

To read more about the Desmoid Tumors Patient Population of the report, click here for Desmoid Tumors Unmet Needs and Patient Journey @ https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.